Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies.

Abstract

The present study sought to elucidate the prognosis of adult T-cell leukemia-lymphoma (ATL) patients receiving mogamulizumab, a defucosylated anti-CCR4 monoclonal antibody. Progression-free survival (PFS) and overall survival (OS) of ATL patients enrolled in two studies are herein updated, namely NCT00355472 (phase I study of mogamulizumab in relapsed patients with ATL and peripheral T-cell lymphoma) and NCT00920790 (phase II study for relapsed ATL). Of 13 patients with relapsed aggressive ATL in the phase I study, four (31%) survived >3 years. For 26 relapsed patients with aggressive ATL in the phase II study, median PFS was 5.2 months and 1-year PFS was 26%, whereas median OS was 14.4 months, and 3-year OS was 23%. For patients without a rash or who developed a grade 1 rash only, median PFS was 0.8 months, and 1-year PFS was zero, with a median OS of 6.0 months, and 3-year OS of 8%. In contrast, for patients who developed a rash ≥grade 2, median PFS was 11.7 months, and 1-year PFS was 50%, with a median OS of 25.6 months, and 3-year OS of 36%. Thus, we conclude that mogamulizumab monotherapy may improve PFS and OS in some patients with relapsed aggressive ATL, especially those who develop a skin rash as a moderate immune-related adverse event. Therefore, further investigation is warranted to validate the present observations and to clarify the mechanisms involved in the activity of mogamulizumab.

• Authors: Takashi Ishida, Atae Utsunomiya, Tatsuro Jo, Kazuhito Yamamoto, Koji Kato, Shinichiro Yoshida, Shigeki Takemoto, Hitoshi Suzushima, Yukio Kobayashi, Yoshitaka Imaizumi, Kenichi Yoshimura, Kouichi Kawamura, Takeshi Takahashi, Kensei Tobinai, Ryuzo Ueda
• Journal: Cancer science (Cancer Sci) Vol. 108 Issue 10 Pg. 2022-2029 (Oct 2017) ISSN: 1349-7006 [Electronic] England
• PMID: 28776876 (Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article)
• Copyright: © 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Chemical References

• Antibodies, Monoclonal, Humanized
• mogamulizumab

Topics

• Aged
• Antibodies, Monoclonal, Humanized (administration & dosage, therapeutic use)
• Disease-Free Survival
• Female
• Humans
• Leukemia-Lymphoma, Adult T-Cell (drug therapy)
• Male
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy)
• Survival Analysis
• Treatment Outcome